RNA Quantification with Gold Nanoprobes for Cancer Diagnostics

Clinics in Laboratory Medicine

Volumn 32, Issue 1, 2012, Pages 1-13

  Baptista, Pedro V ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Cancer; Gold nanoparticles; Molecular diagnostics; Nanodiagnostics; RNA; RNA quantification

Indexed keywords

BIOLOGICAL MARKER; GOLD NANOPARTICLE; MICRORNA;

ALTERNATIVE RNA SPLICING; CANCER DIAGNOSIS; DNA DETERMINATION; DNA SEQUENCE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; NANOPROBE; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; RNA PROCESSING; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

GOLD; HUMANS; METAL NANOPARTICLES; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84857086531     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2011.09.001     Document Type: Review

References (98)

1. Centers for Disease Control and Prevention, Accessed August 10, 2011. http://www.cdc.gov.
2. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
3. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. Jain K.K. Advances in the field of nanooncology. BMC Medicine 2010, 8:83.
5. Choi Y.E., Kwak J.W., Park J.W. Nanotechnology for early cancer detection. Sensors 2010, 10:428-455.
6. Balmain A., Gray J., Ponder B. The genetics and genomics of cancer. Nat Genet 2003, 33(Suppl):238-244.
7. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
8. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
9. Bell D.W. Our changing view of the genomic landscape of cancer. J Pathol 2010, 220:231-243.
10. Harris T.J., McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010, 7:251-265.
11. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
12. Iacobuzio-Donahue C.A. Epigenetic changes in cancer. Annu Rev Pathol 2009, 4:229-249.
13. Irminger-Finger I., Jefford C.E. Is there more to BARD1 than BRCA1?. Nat Rev Cancer 2006, 6:382-391.
14. Lewis P.D., Parry J.M. In silico p53 mutation hotspots in lung cancer. Carcinogenesis 2004, 25:1099-1107.
15. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370:342-350.
16. Shet A.S., Jahagirdar B.N., Verfaillie C.M. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002, 16:1402-1411.
17. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
18. Wong S., Witte O.N. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004, 22:247-306.
19. Melo J. Inviting leukemic cells to waltz with the devil. Nat Med 2001, 7:156-157.
20. Goodstadt L., Ponting C.P. Sequence variation and disease in the wake of the draft human genome. Hum Mol Genet 2001, 10:2209-2214.
21. Weber J.L., David D., Heil J., et al. Human diallelic insertion/deletion polymorphisms. Am J Hum Genet 2002, 71:854-862.
22. Den Dunnen J.T., Antonarakis S.E. Nomenclature for the description of human sequence variations. Hum Genet 2001, 109:121-124.
23. Human mutation databases UK HGMP Resource Center, Accessed August 10, 2011. http://www.biologie.uni-hamburg.de/b-online/library/genomeweb/GenomeWeb/human-gen-db-mutation.html.
24. Tabor H.K., Risch N.J., Myers R.M. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002, 3:391-397.
25. Wheeler D.L., Church D.M., Federhen S., et al. Database resources of the National Center for Biotechnology. Nucleic Acids Res 2003, 31:28-33.
26. Celera Accessed August 10, 2011. http://www.celera.com.
27. dbSNP Short genetic variations National Center for Biotechnology Information, Accessed August 10, 2011. http://www.ncbi.nlm.nih.gov/SNP/index.html.
28. A genotype-phenotype association database GWAS Central, Accessed August 10, 2011. http://www.gwascentral.org.
29. The human gene mutation database Accessed August 10, 2011. http://www.hgmd.org.
30. International HapMap Project, Accessed August 10, 2011. http://snp.cshl.org.
31. Tan I.B., Ngeow J., Tan P. Role of polymorphisms in cancer susceptibility. eLS 2010.
32. Maskos U., Southern E.M. Oligonucleotide hybridizations on glass supports: a novel linker for oligonucleotide synthesis and hybridization properties of oligonucleotides synthesised in situ. Nucleic Acids Res 1992, 20:1679-1684.
33. Schena M., Shalon D., Davis R.W., et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467-470.
34. Mardis E.R. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008, 9:387-402.
35. Metzker M.L. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46.
36. Chee-Seng K., En Yun L., Yudi P., et al. Next generation sequencing technologies and their applications. eLS 2010.
37. Su Z., Ning B., Fang H., et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn 2011, 11:333-343.
38. Copeland N.G., Jenkins N.A. Deciphering the genetic landscape of cancer - from genes to pathways. Trends Genet 2009, 25:455-462.
39. Van Kouwenhove M., Kedde M., Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011, 11:644-656.
40. Ballestar E. An introduction to epigenetics. Adv Exp Med Biol 2011, 711:1-11.
41. Croce C.M. miRNAs in the spotlight: understanding cancer gene dependency. Nat Med 2011, 17:935-936.
42. Hager G.L., McNally J.G., Misteli T. Transcription dynamics. Mol Cell 2009, 35:741-753.
43. David C.J., Manley J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010, 24:2343-2364.
44. Inui M., Martello G., Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010, 11:252-263.
45. Dykxhoorn D.M. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 2010, 70:6401-6406.
46. Hawkins R.D., Hon G.C., Ren B. Next-generation genomics: an integrative approach. Nat Rev Genet 2010, 11:476-486.
47. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
48. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11:426-437.
49. Munker R., Calin G.A. MicroRNA profiling in cancer. Clin Sci (Lond) 2011, 121:141-158.
50. Mendrick D.L. Transcriptional profiling to identify biomarkers of disease and drug response. Pharmacogenomics 2011, 12:235-249.
51. Woodgate L., Mills K. Reverse Transcription and PCR. eLS 2003.
52. NCI Alliance for Nanotechnology in Cancer National Cancer Institute, Accessed August 10, 2011. http://nano.cancer.gov/.
53. Hede S., Huilgol N. "Nano": the new nemesis of cancer. J Cancer Res Ther 2006, 2:186-195.
54. Baptista P. Cancer nanotechnology - prospects for cancer diagnostics and therapy. Curr Cancer Ther Rev 2009, 5:80-88.
55. Selvan S.T., Tan T.T., Yi D.K., et al. Functional and multifunctional nanoparticles for bioimaging and biosensing. Langmuir 2010, 26:11631-11641.
56. Jain K.K. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 2005, 4:645-650.
57. Condon A. Designed DNA molecules: principles and applications of molecular nanotechnology. Nat Rev Genet 2006, 7:565-575.
58. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
59. Liu C.H., Li Z.P., Du B.A., et al. Silver nanoparticle-based ultrasensitive chemiluminescent detection of DNA hybridization and single-nucleotide polymorphisms. Anal Chem 2006, 78:3738-3744.
60. Baptista P., Pereira E., Eaton P., et al. Gold nanoparticles for the development of clinical diagnosis methods. Anal Bioanal Chem 2008, 391:943-950.
61. Huang X., Jain P.K., El-Sayed I.H., et al. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond) 2007, 2:681-693.
62. Vo-Dinh T., Wang H., Scaffidi J. Plasmonic nanoprobes for SERS biosensing and bioimaging. J Biophotonics 2010, 3:89-102.
63. Aslan K., Huang J., Wilson G.M., et al. Metal-enhanced fluorescence-based RNA sensing. J Am Chem Soc 2006, 128:4206-4207.
64. Sun L., Irudayaraj J. PCR-free quantification of multiple splice variants in a cancer gene by surface-enhanced Raman spectroscopy. J Phys Chem B 2009, 113:14021-14025.
65. Noor M., Goyal S., Christensen S., et al. Electrical detection of single-base DNA mutation using functionalized nanoparticles. Appl Phys Let 2009, 95. 073703.
66. Han G., Xing Z., Dong Y., et al. One-step homogeneous DNA assay with single-nanoparticle detection. Angew Chem Int Ed Engl 2011, 50:3462-3465.
67. Qiu F., Gu K., Yang B., et al. DNA assay based on monolayer-barcoded nanoparticles for mass spectrometry in combination with magnetic microprobes. Talanta 2011, 85:1698-1702.
68. Pissuwan D., Valenzuela S.M., Cortie M.B. Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol 2006, 24:62-67.
69. Li Y., Wark A.W., Lee H.J., et al. Single-nucleotide polymorphism genotyping by nanoparticle-enhanced surface plasmon resonance imaging measurements of surface ligation reactions. Anal Chem 2006, 78:3158-3164.
70. Yao X., Li X., Toledo F., et al. Sub-attomole oligonucleotide and p53 cDNA determinations via a high-resolution surface plasmon resonance combined with oligonucleotide-capped gold nanoparticle signal amplification. Anal Biochem 2006, 354:220-228.
71. Moores A., Goettmann F. The plasmon band in noble metal nanoparticles: an introduction to theory and applications. New J Chem 2006, 30:1121-1132.
72. Schasfoort R.B., Schuck P. Future trends in SPR technology. Handbook of surface plasmon resonance 2008, 354-394. RSC, Cambridge (UK). R.B. Schasfoort, A.J. Tudos (Eds.).
73. Guler U., Turan R. Effect of particle properties and light polarization on the plasmonic resonances in metallic nanoparticles. Opt Express 2010, 18:17322-17338.
74. Turkevich J. Colloidal gold - Part II. Gold Bull 1985, 18:125.
75. Liz-Marzan L. Tailoring surface plasmons through the morphology and assembly of metal nanoparticles. Langmuir 2006, 22:32-41.
76. Link S., El-Sayed M. Spectral properties and relaxation dynamics of surface plasmon electronic oscillations in gold and silver nanodots and nanorods. J Phys Chem B 1999, 103:8410-8426.
77. Burda C., Chen X., Narayanan R., et al. Chemistry and properties of nanocrystals of different shapes. Chem Rev 2005, 105:1025-1102.
78. El-Sayed M. Some interesting properties of metals confined in time and nanometer space of different shapes. Acc Chem Res 2001, 34:257-264.
79. Jain P., Lee K., El-Sayed I., et al. Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine. J Phys Chem B 2006, 110:7238-7248.
80. Li H., Rothberg L. Colorimetric detection of DNA sequences based on electrostatic interactions with unmodified gold nanoparticles. Proc Natl Acad Sci U S A 2004, 101:14036-14039.
81. Lee H., Joo S., Lee S., et al. Colorimetric genotyping of single nucleotide polymorphism based on selective aggregation of unmodified gold nanoparticles. Biosens Bioelectron 2010, 26:730-735.
82. Kanjanawarut R., Su X. Colorimetric detection of DNA using unmodified metallic nanoparticles and peptide nucleic acid probes. Anal Chem 2009, 81:6122-6129.
83. Liu M., Yuan M., Lou X., et al. Label-free optical detection of single-base mismatches by the combination of nuclease and gold nanoparticles. Biosens Bioelectron 2011, 26:4294-4300.
84. Hurst S., Lytton-Jean A., Mirkin C. Maximizing DNA loading on a range of gold nanoparticle sizes. Anal Chem 2006, 78:8313-8318.
85. Thaxton C., Georganopoulou D., Mirkin C. Gold nanoparticle probes for the detection of nucleic acid targets. Clin Chim Acta 2006, 363:120-126.
86. Sato K., Hosokawa K., Maeda M. Colorimetric biosensors based on DNA-nanoparticle conjugates. Anal Sci 2007, 23:17-20.
87. Ogawa A., Maeda M. Simple and rapid colorimetric detection of cofactors of aptazymes using noncrosslinking gold nanoparticle aggregation. Bioorg Med Chem Lett 2008, 18:6517-6520.
88. Cao Y.C., Jin R.C., Mirkin C.A. Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science 2002, 281:1536-1540.
89. Huber M., Wei T., Müller U.R., et al. Gold nanoparticle probe-based gene expression analysis with unamplified total human RNA. Nucleic Acids Res 2004, 32:e137.
90. Liang R.Q., Li W., Li Y., et al. An oligonucleotide microarray for microRNA expression analysis based on labeling RNA with quantum dot and nanogold probe. Nucleic Acids Res 2005, 33:e17.
91. Baptista P., Doria G., Henriques D., et al. Colorimetric detection of eukaryotic gene expression with DNA-derivatized gold nanoparticles. J Biotechnol 2005, 119:111-117.
92. Doria G., Franco R., Baptista P. Nanodiagnostics: fast colorimetric method for single nucleotide polymorphism/mutation detection. IET Nanobiotechnol 2007, 1:53-57.
93. Veigas B., Machado D., Perdigão J., et al. Au-nanoprobes for detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis. Nanotechnology 2010, 21:415101.
94. Costa P., Amaro A., Botelho A., et al. Gold nanoprobe assay for the identification of mycobacteria of the Mycobacterium tuberculosis complex. Clin Microbiol Infect 2010, 16:1464-1469.
95. Silva L.B., Veigas B., Doria G., et al. Portable optoelectronic biosensing platform for identification of mycobacteria from the Mycobacterium tuberculosis complex. Biosens Bioelectron 2011, 26:2012-2017.
96. Conde J., de la Fuente J.M., Baptista P.V. RNA quantification using gold nanoprobes - application to cancer diagnostics. J Nanobiotechnology 2010, 8:5.
97. Baptista PV, Doria G, Conde J. Alloy metal nanoparticles for multicolor cancer diagnostics. In: Proceeding of SPIE Vol. 7909 79090K-1, SPIE West 2011, Colloidal Quantum Dots/Nanocrystals for Biomedical Applications VI. San Francisco (CA): 2011.
98. Doria G., Larguinho M., Dias J.T., et al. Gold-silver-alloy nanoprobes for one-pot multiplex DNA detection. Nanotechnology 2010, 21:255101.